

RELEASE FROM ESCROW

Adelaide, Australia, 3 January 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**) announces the release from escrow, on 31 December 2022, of 30,660,377 LBT ordinary shares (**Shares**).

The Shares are held by Hettich Holding Beteiligungs-und Verwaltungs-GMBH (**Hettich**). The Shares were issued to Hettich on 30 December 2021, subject to voluntary escrow, as part consideration for the acquisition of Hettich's 50% shareholding of the Clever Culture Systems joint venture (refer ASX announcements on 29 December 2021 and 4 January 2022).

Approved for release by the Company Secretary.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com